International Journal of Rheumatic Diseases最新文献

{"title":"Flagellate Erythema: An Indicator of Underlying Malignancy in Dermatomyositis","authors":"Hieu Chi Ha, On Bon Louis Chan, Anousha Yazdabadi, Christopher Meng Kit Fong","doi":"10.1111/1756-185x.70534","DOIUrl":"10.1111/1756-185x.70534","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deforming Arthritis as a New Rheumatologic Manifestation of Cocaine Use","authors":"Michael A. Vierra, Amr Edrees","doi":"10.1111/1756-185x.70529","DOIUrl":"10.1111/1756-185x.70529","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Multifaceted Role of p53 in Musculoskeletal Diseases: A Comprehensive Review","authors":"Marofe Hossain,&nbsp;Sun Hao,&nbsp;Ahamed Yeasin,&nbsp;Yongxiang Wang","doi":"10.1111/1756-185x.70523","DOIUrl":"10.1111/1756-185x.70523","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>While extensively studied for its central role in tumor suppression (regulating cell cycle, DNA repair, and apoptosis), the p53 gene is now recognized for its significant involvement in musculoskeletal diseases. Aberrant p53 expression and function are key factors in the pathogenesis and progression, although the specific mechanisms and clinical change potential remain incompletely defined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This review systematically summarizes the multifaceted roles of p53 in major musculoskeletal diseases, analyzes the molecular mechanisms driving disease progression, and evaluates its potential as a therapeutic target.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive literature search was conducted in PubMed January 2008 to March 2025 using keywords including P53, osteoporosis, osteoarthritis, rheumatoid arthritis, gout, low back pain, and scoliosis. Original research, reviews, and clinical trials focusing on p53 mechanisms were included. 90 relevant articles were selected for analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results &amp; Conclusion</h3>\u0000 \u0000 <p>p53 critically influences the development and progression of musculoskeletal diseases (osteoporosis, osteoarthritis, rheumatoid arthritis, low back pain, gout, and scoliosis) through diverse mechanisms: Disrupting bone formation/resorption balance (via the p53-Nedd4-Runx2 axis in osteoporosis). Promoting chondrocyte apoptosis (via the miR-34a-SIRT1-p53 pathway in osteoarthritis). Modulating inflammatory mediators (TNF-α, IL-6 in rheumatoid arthritis). Regulating oxidative stress responses (p53-SLC2A9 axis in gout). p53 exhibits dual roles (pro-apoptotic vs. anti-inflammatory), necessitating precise targeting strategies. Promising therapeutic interventions include p53-focused gene editing (CRISPR/Cas9), small-molecule inhibitors (PFT-α), and natural products (naringin). However, further clinical validation is essential. Future research requires multidisciplinary approaches to deepen understanding of p53 mechanisms and advance clinical applications in musculoskeletal disorders.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Lupus Erythematosus and Multiple Sclerosis Overlap After Adalimumab Therapy: A Case Report","authors":"María García-González,&nbsp;Andrea Fernández-Valmaña,&nbsp;Jesús Alberto López-Martínez,&nbsp;Marta Ros-Segura,&nbsp;Carlos Feijoo-Massó","doi":"10.1111/1756-185x.70527","DOIUrl":"10.1111/1756-185x.70527","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 12","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Significance of CCL17 in Psoriatic Arthritis","authors":"Kevin Ming-Chin Lee,&nbsp;Adrian A. Achuthan,&nbsp;Matthew Jiang,&nbsp;John A. Hamilton,&nbsp;Keith Lim","doi":"10.1111/1756-185x.70526","DOIUrl":"10.1111/1756-185x.70526","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 12","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of Rheumatic and Musculoskeletal Disorders in Province 3 of Nepal: A COPCORD-Based Community Survey","authors":"Binit Vaidya,&nbsp;Shweta Nakarmi","doi":"10.1111/1756-185x.70507","DOIUrl":"10.1111/1756-185x.70507","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 12","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tocilizumab in the Treatment of Sporadic Inclusion Body Myositis","authors":"Cheng Xu,&nbsp;Ning Shen,&nbsp;Yongmei Han","doi":"10.1111/1756-185x.70521","DOIUrl":"10.1111/1756-185x.70521","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 12","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Pneumocystis Pneumonia in Patients With Rheumatoid Arthritis and the Role of Prophylactic Salazosulfapyridine","authors":"Ryo Sato,&nbsp;Kenya Terabe,&nbsp;Takahiro Imaizumi,&nbsp;Koji Sakamoto,&nbsp;Kikue Sato,&nbsp;Junya Hasegawa,&nbsp;Takaya Sugiura,&nbsp;Yusuke Ono,&nbsp;Mochihito Suzuki,&nbsp;Shuji Asai,&nbsp;Shiro Imagama","doi":"10.1111/1756-185x.70516","DOIUrl":"10.1111/1756-185x.70516","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to assess the risk factors for <i>Pneumocystis</i> pneumonia (PCP) in patients with rheumatoid arthritis (RA) and investigate the potential of salazosulfapyridine (SASP) as a prophylactic agent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The present study analyzed data from the Japanese Diagnosis Procedure Combination database, which provides comprehensive inpatient data (including diagnoses, procedures, and medications) covering a large portion of the population. We identified patients with RA who developed PCP among 14 190 patients diagnosed with RA at admission with a treatment history. Patients with RA who were receiving therapeutic doses of drugs for PCP were defined as having PCP. A nested case–control analysis was performed to compare patients with RA and PCP with age- and sex-matched control patients with RA without PCP in a ratio of 1:20.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The cohort comprised 132 patients with PCP and 2575 controls. The risk factors for PCP in RA were chronic obstructive pulmonary disease, methotrexate (MTX), biological/targeted synthetic DMARDs (b/tsDMARDs), and high-dose glucocorticoids. SASP may have a protective effect against PCP, particularly in patients with RA treated with MTX and/or b/tsDMARDs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The large sample size of the present study suggests that SASP may be associated with a reduced PCP risk in RA patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 12","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variable Expression of CD62L (L-Selectin) on Various White Blood Cells in Rheumatoid Arthritis","authors":"Bidyalaxmi Leishangthem,&nbsp;Aastha Khullar,&nbsp;Chandra Bhushan Prasad,&nbsp;Sankar Jayaprakash,&nbsp;Siddharth Jain,&nbsp;Varun Dhir","doi":"10.1111/1756-185x.70519","DOIUrl":"10.1111/1756-185x.70519","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 12","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual Mechanisms of Hyperuricemia-Associated Renal Injury: A Systematic Review of Crystal-Dependent and Crystal-Independent Pathways","authors":"Gudisa Bereda,&nbsp;Felix Pius Omullo","doi":"10.1111/1756-185x.70493","DOIUrl":"10.1111/1756-185x.70493","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hyperuricemia, marked by elevated uric acid levels, is associated with renal disorders like acute kidney injury and chronic kidney disease, through both crystal-dependent and crystal-independent mechanisms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This review aims to evaluate the crystal-dependent and crystal-independent mechanisms by which hyperuricemia induces renal injury.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>A systematic review of the literature.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Participants</h3>\u0000 \u0000 <p>Human and animal studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Measurements</h3>\u0000 \u0000 <p>A total of 1549 articles were initially identified from PubMed, Web of Science, Scopus, and Google Scholar. After removing 659 duplicates and screening titles and abstracts, 572 articles were excluded, and 16 could not be retrieved, leaving 302 for full-text review. Of these, 17 studies met the eligibility criteria and were included. Risk of bias was assessed using SYRCLE for animal studies, ROB2 for human studies, and NOS for observational studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From 17 studies: nine animal experiments, one human experiment, and seven observational studies. Animal studies showed hyperuricemia causes preglomerular arteriolopathy, glomerular hypertension, and worsens nephrotoxicity. Human studies demonstrated elevated uric acid, even without crystals, activates intrarenal RAS, increases oxidative stress, and reduces nitric oxide. Clinical studies confirmed high uric acid is linked to CKD progression, with very low levels also risky (“J-shaped” relationship). Endothelial dysfunction is a unifying mechanism, promoting inflammation and fibrosis in crystal-dependent injury and vasoconstriction and renal damage in crystal-independent injury.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This review confirmed that hyperuricemia damages the kidney through both crystal-dependent and crystal-independent pathways, with endothelial dysfunction as a key mediator. Further human studies are needed to confirm these findings and explore new treatments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 12","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}